IgA Nephropathy (IgAN): Clinical Trials

2 trials for IgA Nephropathy (IgAN), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 recruiting. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Not yet recruiting 1, Recruiting 1

Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Phase 4Not yet recruitingUniversity of Illinois at Chicago202026-09-292026-09-21
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
NEFECON, Placebo - IgA Nephropathy (IgAN)
Phase 4RecruitingNanfang Hospital, Southern Medical University2882026-06-232026-09-02

Narrower conditions

Glomerulonephritis, IGA (2)  ·  Fibrosis (1)

Broader conditions

Autoimmune Diseases (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Glomerulonephritis (2)  ·  Immune System Diseases (2)  ·  Kidney Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Nephritis (2)  ·  Urogenital Diseases (2)  ·  Urologic Diseases (2)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Atrasentan (1)

Sponsors

Nanfang Hospital, Southern Medical University (1)  ·  University of Illinois at Chicago (1)

Countries

China (1)  ·  United States (1)

Top investigators

Anand Srivastava, MD, MPH (1)